Print Page | Sign In | Join
Business Wire Life Sciences News (US)
Share |

ImmunoGen Announces Webcasts of Presentations at Upcoming ConferencesOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: 2018 Cantor Global Healthcare ConferenceOctober 2 at 2:50pm ET Leerink Partners Roundtable SeriesOctober 3 at 9:30am ET A webcast of each presentation will be accessible live through the “Investors” section of the Com

 

Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare ConferenceOpen in a New Window

NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Cantor Fitzgerald 2018 Global Healthcare Conference in New York, NY. President and Chief Executive Officer, Dan Browne, is scheduled to present on Tuesday, October 2 at 11:30am ET. Interested parties can access the live audio webcast for this conference from

 

TP Therapeutics Announces Updated Interim Phase 1/2 Clinical Trial Data of Repotrectinib (TPX-0005) in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer Patients at 19th World Conference on Lung CancerOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--TP Therapeutics Announces Updated Interim Phase 1/2 Clinical Trial Data of Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer Patients

 

Verastem Oncology Receives FDA Approval of COPIKTRA™ (duvelisib) CapsulesOpen in a New Window

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has approved COPIKTRA™, an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma. COPIKTRA is approved for the treatment of adult patients with relapsed or refract

 

Global Elemental Analysis Market 2018-2022| Increased Adoption among Academic Institutions to Boost Demand| TechnavioOpen in a New Window

LONDON--(BUSINESS WIRE)--#LifeScience--Technavio analysts forecast the global elemental analysis market to grow at a CAGR of over 6% during the period 2018-2022, according to their report.

 

Diabetic Retinopathy - A Drug Pipeline Analysis Report by TechnavioOpen in a New Window

LONDON--(BUSINESS WIRE)--#RareDiseases--Technavio has published a new report on the drug pipeline for the treatment of diabetic retinopathy, including a detailed study of the molecules.

 

OncLive® and The Ruesch Center Announce the Honorees of The Luminary Awards in GI CancersOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)--OncLive® and The Ruesch Center Announce the Honorees of The Luminary Awards in GI Cancers

 

Cook Medical Receives FDA Approval for First 5 mm Diameter SFA Drug-Eluting StentOpen in a New Window

BLOOMINGTON, Ind.--(BUSINESS WIRE)--Cook Medical announced that a new 5 mm diameter version of Zilver® PTX® was approved by the FDA. It is the first 5 mm drug-eluting stent in the U.S. with lengths available up to 140 mm that is indicated to treat vessels as small as 4mm in diameter. The range of Zilver PTX stent diameters now available will address treatment of vessel sizes from 4–7 mm in diameter. The new diameter is better sized for smaller anatomy than previous sizes of the stent and provid

 

Landmark Lipid-Rich Plaque (LRP) Study Results Demonstrate the Ability to Accurately Identify Patients and Plaques at Risk for Major Coronary EventsOpen in a New Window

BURLINGTON, Mass.--(BUSINESS WIRE)--Infraredx's Lipid-Rich Plaque (LRP) Study demonstrates the ability to accurately identify patients and plaques at risk for major coronary events.

 

New Food Allergy Diagnostics Company, AllerGenis, Recently Launched to Deliver Innovative Diagnostic Technology Enabling More Precise Food Allergy Detection and Patient ManagementOpen in a New Window

HATFIELD, Pa.--(BUSINESS WIRE)--Food allergy diagnostics company, AllerGenis, recently launched to deliver innovative diagnostic technology enabling precision food allergy detection

 

Battelle Shows NeuroLife System’s Machine Learning Prowess in Nature MedicineOpen in a New Window

COLUMBUS, Ohio--(BUSINESS WIRE)--During the past four years, Battelle scientists and their colleagues at The Ohio State University Wexner Medical Center (OSU) have shown the world that patients with spinal cord injuries can regain movement in their paralyzed limb using the Battelle NeuroLife® system. In a new paper published in the prestigious international journal Nature Medicine they are demonstrating how their advances might help the NeuroLife system emerge from the laboratory and enter the

 

Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial OfficerOpen in a New Window

BOSTON--(BUSINESS WIRE)--Centrexion Therapeutics Corporation, a company focused on developing novel, non-opioid and non-addictive therapies for the treatment of chronic pain, today announced that Andrew Partridge has been appointed Executive Vice President, Chief Commercial Officer of the company. “We are very pleased to have Andrew join the Centrexion leadership team,” said Jeffrey B. Kindler, chief executive officer of Centrexion Therapeutics. “Andrew has a proven ability to develop and energ

 

Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer PatientsOpen in a New Window

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients

 

PartsSource Expands Leadership Team With David Brennan as Vice President and General Manager, ServiceOpen in a New Window

CLEVELAND--(BUSINESS WIRE)--#HTM--PartsSource adds David Brennan as Vice President, General Manager of Service to focus on fast growing business. Brennan joins from GE Healthcare.

 

CURE® Media Group Launches #MoreThanAPatient CampaignOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)--#MoreThanAPatient--CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, launched #MoreThanAPatient social media campaign on Sept. 24. The campaign features individuals who are telling the public how they are a parent, a runner, a teammate, a child, and most importantly, more than a patient. “Patients who have gone through the cancer journey are more than their diagnosis, they’re #MoreThanAPatient,” said Michael J.

 

Survey Findings Highlight the Burden of Neurogenic Orthostatic Hypotension (nOH) on Patients and Care PartnersOpen in a New Window

DEERFIELD, Ill.--(BUSINESS WIRE)--Results from a nationwide survey highlighting patient and care partner perception of the impact and burden of neurogenic orthostatic hypotension (nOH) and its symptoms point to the need for heightened education and awareness of nOH.1 In the survey publication in BMC Neurology, the authors noted that, “to the best of our knowledge, our study is the first to investigate the impact of nOH from both the patient and caregiver perspective.”1 The survey was developed

 

MedTech Innovator Announces Newest Industry PartnersOpen in a New Window

LOS ANGELES--(BUSINESS WIRE)--MedTech Innovator, the premier nonprofit startup accelerator in the medical technology industry, today announced eight new partnerships with healthcare industry leaders -- Amgen, BTG, EdgeOne Medical, Fujikura Ltd., HOYA Corp., NIPRO Medical Corp., Nordson Medical, and W. L. Gore & Associates, Inc. MedTech Innovator’s external innovation program matches healthcare industry leaders with the most promising early-stage medtech companies in the world for mentorship

 

LabCorp Teams up with Operation Airdrop to Deliver Much-Needed Supplies to North Carolina Communities Devastated by Hurricane FlorenceOpen in a New Window

BURLINGTON, N.C.--(BUSINESS WIRE)--Over the weekend, LabCorp® (NYSE: LH) in coordination with Operation Airdrop delivered approximately 25,000 pounds of water, food, dog food, diapers, and other relief supplies as well as 1,000 hot meals aboard three of LabCorp’s Pilatus PC-12 cargo aircraft to aid in recovery efforts following Hurricane Florence. “We were asked to assist Operation Airdrop with transporting relief supplies that exceeded the capacity of other aircraft, and within hours our pilot

 

Emergent BioSolutions Expands Manufacturing Capability with ABEC Dual Purpose Single-Use Microbial Fermentation / Mammalian Cell Culture SystemsOpen in a New Window

BETHLEHEM, Pa.--(BUSINESS WIRE)--#Mammalian--Emergent BioSolutions Expands Manufacturing Capability with ABEC Dual Purpose Single-Use Microbial Fermentation / Mammalian Cell Culture Systems

 

MEDISCA’s Proactive Position towards Regulatory EnforcementOpen in a New Window

PLATTSBURGH, N.Y.--(BUSINESS WIRE)--#Compliance--MEDISCA, a global leader in the pharmaceutical compounding industry, strives to proactively strengthen their quality systems and adhere to regulatory requirements and enforcement. MEDISCA is a company with a global presence and operates facilities in several countries while complying with the different regulations. Our internal policies and procedures are created and implemented throughout our organization as a global standard encompassing the industry’s regu

 

McKesson Medical-Surgical and ILÚM Health Solutions Announce Distribution Alliance in Community Hospital MarketOpen in a New Window

RICHMOND, Va.--(BUSINESS WIRE)--McKesson Medical-Surgical Inc., an affiliate of the McKesson Corporation, has signed an exclusive agreement with ILÚM Health Solutions, part of Merck & Co, Inc.’s Healthcare Services and Solutions business, that provides innovative technology and services to support infectious disease management, to serve the U.S. community hospital market. This agreement highlights the companies’ shared focus on supporting community hospitals to improve patient safety and co

 

Advanced Bifurcation Systems Unveils at TCT 2018 Patented Stenting Platform Reducing Need for Open-Heart SurgeriesOpen in a New Window

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ABS unveils patented bifurcation stenting platform to standardize the treatment of all bifurcation lesions in coronary angioplasties.

 

Baron & Budd Investigating Medicare and Medicaid Fraud in Patient Assistance Programs for Specialty DrugsOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--The national law firm Baron & Budd is investigating fraud in Patient Assistance Programs (PAPs) for specialty drugs.

 

Genentech’s Investigational Medicine Entrectinib Showed a Durable Response of More Than Two Years in People With a Specific Type of Lung CancerOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA trials, which showed that entrectinib shrank tumors (objective response rate; ORR) in 77.4 percent of people with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). In addition, entrecti

 

Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in a Type of Previously Untreated Advanced Lung CancerOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the Phase III IMpower132 study of TECENTRIQ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). This interim analysis showed that TECENTRIQ and chemotherapy reduced the risk of disease worsening or death (progres

 

Batu Biologics Announces the Release of the Starve The Tumor Immunotherapy BlogOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Today, Batu Biologics announced the release of the Starve The Tumor Video Blog, a series of informational videos and articles designed to provide background information on our lead therapeutic ValloVax. Batu Biologics’ lead clinical candidate, ValloVax, is a first-in-class placenta derived endothelial cell based vaccine designed to stimulate an immune response against several tumor angiogenesis associated antigens for the treatment of solid tumor carcinomas. Currentl

 

Cerveau Technologies Inc. Signs Research Agreement with Ionis Pharmaceuticals, Inc. for Novel Tau Imaging AgentOpen in a New Window

BOSTON, Mass.--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with Ionis Pharmaceuticals, Inc. for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. The collaboration is focused

 

GeneCentric Therapeutics Licenses Pancreatic Cancer Subtyping Technology from University of North CarolinaOpen in a New Window

DURHAM, N.C.--(BUSINESS WIRE)--GeneCentric Therapeutics Licenses Pancreatic Cancer Subtyping Technology from University of North Carolina

 

ARTMS’ QUANTM Irradiation System™ to Be Featured at Two International Conferences in SeptemberOpen in a New Window

VANCOUVER, British Columbia--(BUSINESS WIRE)--ARTMS Products, Inc. announced today that it has been invited to present at the National Nuclear Security Administration’s 2018 Mo-99 Topical Meeting on Tuesday, September 25th and the Third International Symposium on Technetium and other Radiometals in Chemistry and Medicine on Thursday, September 27th. Joel Kumlin will present at the 2018 Mo-99 Topical Meeting in Knoxville, TN, during Session 7, Production Projects and Technologies II, at 13:00EDT

 

Mawi DNA Technologies Launches iSWAB Cell Stabilization Product LineOpen in a New Window

HAYWARD, Calif.--(BUSINESS WIRE)--#BassamElFahmawi--Mawi DNA Technologies, a biotechnology company focusing on technologies for biosampling, announces the launch of iSWAB-Cells.

 

BayCross Capital Advises Renovia on $42.3M FinancingOpen in a New Window

BOSTON--(BUSINESS WIRE)--BayCross Capital Group, LLC (“BayCross”), a consulting and advisory firm specializing in capital optimization as well as debt and equity raises, is pleased to announce that it advised Renovia Inc (“Renovia”), a company dedicated to discovering and delivering first-line digital therapeutic and diagnostic devices for women with pelvic floor disorders, on its $42.3M financing. The funding consisted of $32.3 million in Series B equity and $10 million in venture debt. “We ar

 

D2 Consulting’s Actionable Market Access Strategies Optimize Reimbursement for Pharmaceutical, Device and Digital Therapy Product LaunchesOpen in a New Window

ST. CHARLES, Mo.--(BUSINESS WIRE)--D2 Consulting’s Actionable Market Access Strategies Optimize Reimbursement for Pharmaceutical, Device and Digital Therapy Product Launches

 

Bluestar Genomics Scientists Non-Invasively Detect Epigenomic Signatures of Early Pancreatic CancerOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--#PanCan--Bluestar Genomics scientists non-invasively detect epigenomic signatures of early pancreatic cancer in cell-free DNA samples

 

Biedermann Motech to Launch iMAS 360™ Procedure at NASSOpen in a New Window

MIAMI--(BUSINESS WIRE)--#100yearsofinnovation--Biedermann Motech will launch the iMAS 360™ procedure at NASS 2018 in Los Angeles, September 26-28, 2018. Biedermann Motech, the developer of the world’s first polyaxial pedicle screw (MOSS System) and pioneer in the spinal market for more than 30 years, announced today the launch of the iMAS 360™ procedure at the North American Spine Society (NASS) meeting in Los Angeles, September 26-28, 2018. The iMAS 360 is a mini-open, microsurgical 360 fusion procedure for the lumb

 

Good Neighbor Pharmacy Receives “Highest in Customer Satisfaction with Chain Drug Store Pharmacies” from J.D. PowerOpen in a New Window

VALLEY FORGE, Pa.--(BUSINESS WIRE)--Today, Good Neighbor Pharmacy – a national independent pharmacy network offered through AmerisourceBergen – announced that it has been ranked “Highest in Customer Satisfaction with Chain Drug Store Pharmacies” in the J.D. Power 2018 U.S. Pharmacy Study. This marks the seventh time that Good Neighbor Pharmacy has earned the achievement in the last nine years. “The key trends highlighted in this study confirm what we see on a daily basis: consumers love their c

 

Magenta Therapeutics Added to Russell 2000 and 3000 IndexesOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the company has been added to the Russell 2000 and 3000 indexes following the Russell U.S. Indexes’ quarterly update. The Russell 3000 index includes the 3,000 largest U.S. companies by market capitalization. Membership in the Russell 3000® Index means automatic inclus

 

Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis COpen in a New Window

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will launch at a list price of $24,000 for the most common course of therapy and will be avail

 

Lumos Pharma Acquires Candidate for Oral Treatment of Growth Hormone DeficiencyOpen in a New Window

AUSTIN, Texas--(BUSINESS WIRE)--#growthhormonedeficiency--Lumos Pharma Acquires Candidate for Oral Treatment of Growth Hormone Deficiency

 

American Shared Hospital Services to Present at the Sidoti & Company Fall 2018 ConferenceOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--American Shared Hospital Services to Present at the Sidoti & Company Fall 2018 Conference on September 27th, 2018 at 10:55 a.m. ET in New York, NY.

 

ZappRx Announces Partnership with Dunn Meadow Specialty PharmacyOpen in a New Window

BOSTON--(BUSINESS WIRE)--ZappRx announced today its partnership with Dunn Meadow specialty pharmacy at NASP 2018.

 

Apollo Endosurgery and Istituto Clinico Humanitas in Milano, Italy Establish European Registry for Flexible Endoscopic Suturing Procedures in Gastrointestinal ApplicationsOpen in a New Window

AUSTIN, Texas--(BUSINESS WIRE)--Apollo and Istituto Clinico Humanitas Establish European Registry for Flexible Endoscopic Suturing Procedures in Gastrointestinal Applications

 

Synergy Pharmaceuticals Strengthens Coverage for TRULANCE® (plecanatide) with Key New Market Access WinsOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Strengthens Coverage for TRULANCE® (plecanatide) with Key New Market Access Wins

 

Ancora Heart Announces Positive Interim Analysis from Study of First-of-Its-Kind Heart Failure TherapyOpen in a New Window

SANTA CLARA, Calif.--(BUSINESS WIRE)--Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced positive clinical data from the company’s recently expanded U.S. early feasibility study evaluating the safety of the investigational AccuCinch® Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR). The data was presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientifi

 

Heather Bimonte-Nelson, PhD of Arizona State University is the 2018 Arizona Bioscience Educator of the YearOpen in a New Window

CHANDLER, Ariz.--(BUSINESS WIRE)--#ASU--Dr. Heather Bimonte-Nelson will be honored for the diverse and innovative ways that she has inspired students of all ages at the 2018 AZBio Awards.

 

New Study Reveals the Importance of Active-DHA in the Developing BrainOpen in a New Window

PHILADELPHIA--(BUSINESS WIRE)--Vanteres, an innovative biotech company leveraging its biomedical research expertise to develop actively transported lysophospholipids, announces new evidence that demonstrates the critical role of LPC-DHA in normal fetal and infant brain development. The new study, conducted by researchers at Duke-NUS, reveals Active-DHA transported by MFSD2a found at the blood brain barrier plays a physiological role in both brain growth and health during brain development. LPC-

 

Dicerna to Participate in Two Upcoming Investor ConferencesOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna today announced that Douglas M. Fambrough, president and CEO, will participate in two investor conferences in October.

 

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi TherapeuticsOpen in a New Window

PASADENA, Calif.--(BUSINESS WIRE)--$arwr--Arrowhead Pharmaceuticals will host an R&D day on September 24, 2018

 

Dulera (Merck) 2017-2018 U.S. Promotional Audit Report - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Dulera 2017 U.S. Promotional Audit Report" report has been added to ResearchAndMarkets.com's offering. The 5 Key Questions Addressed How many physicians were reached by Dulera through reportable promotional activity in 2017 and how does this compare to its peer set in the Asthma market? What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity? How does Merck's dept

 

Zelapar (Valeant) 2017-2018 U.S. Promotional Audit Report - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Zelapar 2017 U.S. Promotional Audit Report" report has been added to ResearchAndMarkets.com's offering. The 5 Key Questions Addressed How many physicians were reached by Zelapar through reportable promotional activity in 2017 and how does this compare to its peer set in the Parkinson's Disease market? What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity? How do

 

Evarrest (Johnson & Johnson) 2017-2018 U.S. Promotional Audit Report - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Evarrest 2017 U.S. Promotional Audit Report" report has been added to ResearchAndMarkets.com's offering. The 5 Key Questions Addressed How many physicians were reached by Evarrest through reportable promotional activity in 2017 and how does this compare to its peer set in the Surgical Bleeding market? What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity? How do

 

Botox (Allergan) 2017-2018 U.S. Promotional Audit Report - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Botox 2017 U.S. Promotional Audit Report" report has been added to ResearchAndMarkets.com's offering. The 5 Key Questions Addressed How many physicians were reached by Botox through reportable promotional activity in 2017 and how does this compare to its peer set in the Blepharospasm, Facial Wrinkles, Glabellar Lines, Hyperhidrosis, Migraine, Muscle Spasticity, Overactive Bladder, Strabismus, and Torticollis markets? What promotional mix was leveraged (e.g., sales

 

LabCorp Statement on District Court Opinion in ACLA Lawsuit against HHSOpen in a New Window

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp® (NYSE: LH) today issued the following statement regarding the decision from the U.S. District Court for the District of Columbia in ACLA v. Azar on Friday, Sept. 21, to dismiss the laboratory industry’s lawsuit to halt implementation of damaging cuts to Medicare reimbursement for lab testing: “We are deeply disappointed in the district court’s decision and believe that its conclusion that it did not have the authority to act in this matter is erroneou

 

Effient (Daiichi Sankyo) 2017-2018 U.S. Promotional Audit Report - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Effient 2017 U.S. Promotional Audit Report" report has been added to ResearchAndMarkets.com's offering. The 5 Key Questions Addressed How many physicians were reached by Effient through reportable promotional activity in 2017 and how does this compare to its peer set in the Stroke Prevention market? What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity? How does

 

Astrotech Reports Fiscal Year 2018 Financial ResultsOpen in a New Window

AUSTIN, Texas--(BUSINESS WIRE)--$ASTC--Astrotech Corporation (NASDAQ: ASTC) reported its financial results for the fourth quarter and fiscal year ended June 30, 2018.

 

Alpine Immune Sciences Announces Upcoming Scientific PresentationsOpen in a New Window

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced planned poster presentations at scientific meetings highlighting recent preclinical data on ALPN-101, a dual ICOS/CD28 antagonist with the potential to treat autoimmune and inflammatory conditions: 2018 ACR/ARHP Annual Meeting Abstract Title: ALPN-101, a Dual ICOS/CD28 Antagonist

 

Aerpio Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare ConferenceOpen in a New Window

CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Monday, October 1, 2018 at 10:40 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update. The presentation will be webcast live and ma

 

FARXIGA Achieved a Positive Result in the Phase III DECLARE-TIMI 58 Trial, a Large Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 DiabetesOpen in a New Window

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA® (dapagliflozin), the broadest SGLT-2 inhibitor CVOT conducted to date. The trial evaluated the CV outcomes of FARXIGA vs. placebo over a period of up to five years, across 33 countries and in more than 17,000 adults with type 2 diabetes (T2D) who have multiple CV risk factors or established CV disease. In the DECLARE (Dapaglifl

 

ArQule to Present at the Cantor Global Healthcare Conference on October 1, 2018Open in a New Window

BURLINGTON, Mass.--(BUSINESS WIRE)--$ARQL #arql--ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the Cantor Global Healthcare Conference on October 1, 2018, at 2:55pm ET at the InterContinental New York Barclay Hotel in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Eve

 

ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018Open in a New Window

BURLINGTON, Mass.--(BUSINESS WIRE)--$ARQL #arql--ArQule, Inc. (Nasdaq:ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the Leerink Partners Roundtable Series on October 2, 2018, at 8:00am ET at the Lotte New York Palace in New York City. The live webcast of the presentation will be available via the “I

 

AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018Open in a New Window

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018

 

Corindus Announces First Live Transmission of Remote Robotic Demonstration Performed at Transcatheter Cardiovascular Therapeutics 2018 ConferenceOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--First remote interventional procedure using CorPath GRX was broadcast live from Mayo Clinic at TCT 2018 Conference

 

AngioSoma Announces New Ecommerce Platform Featuring Innovative ProductsOpen in a New Window

HOUSTON--(BUSINESS WIRE)--AngioSoma Announces New Ecommerce Platform Featuring Innovative Products.

 

Aerie Pharmaceuticals Announces Appointment of Damien Monaghan, Quality DirectorOpen in a New Window

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Damien Monaghan, Quality Director, reporting to Finbar O’Neill, EU Director, Quality & Regulatory Compliance. Mr. Monaghan will lead quality assurance and qua

 

Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)Open in a New Window

BOSTON--(BUSINESS WIRE)--Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

 

Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical ProgramOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials. Epizyme is now in the process of reopening enrollment in all of its company-sponsored trials in the U.S., including the follicular lymphoma (FL) EZH2 activating mutation cohort of it

 

Immunomic Therapeutics CEO to Present at Precision Medicine World Conference (PMWC): Emerging Therapeutics ShowcaseOpen in a New Window

DURHAM, N.C.--(BUSINESS WIRE)--Dr. William Hearl, CEO of Immunomic Therapeutics, Inc., to present at the Precision Medicine World Conference in the Emerging Therapeutics Showcase.

 

Insulet to Announce Third Quarter 2018 Financial Results on November 1, 2018Open in a New Window

BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the third quarter of 2018 on November 1, 2018 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on t

 

DermTech Announces Publication of “Non-Invasive Gene Expression Testing to Rule Out Melanoma”Open in a New Window

LA JOLLA, Calif.--(BUSINESS WIRE)--#AAD--This validated assay can modify physician behavior and should lead to improved patient care and reduced costs to the health care system.

 

BVGH’s African Access Initiative Featured at Biden Cancer SummitOpen in a New Window

SEATTLE--(BUSINESS WIRE)--BIO Ventures for Global Health (BVGH) was featured at last week’s Biden Cancer Summit, hosted by Vice President Joe Biden and Dr. Jill Biden, for its commitment to addressing Africa’s long under-recognized cancer epidemic through its African Access Initiative (AAI). Facts about cancer in Africa were highlighted by BVGH President, Jennifer Dent, who spoke at the Summit: African women with breast cancer have poor outcomes due to the fact that they present younger and oft

 

Foundation Medicine Introduces FoundationOne®Liquid, the Latest Advance in the Company’s Liquid Biopsy Test for Solid Tumors in Patients with Advanced CancerOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. today announced that FoundationOne®Liquid, its next-generation liquid biopsy test for solid tumors, is commercially available in the United States. Using a blood sample, FoundationOne Liquid analyzes 70 genes known to drive cancer growth, including homologous recombination deficiency (HRD) genes, and reports the genomic biomarker for microsatellite instability (MSI),1 to help inform the use of checkpoint inhibitor immunotherapies and

 

MEBIAS Discovery Receives Grant from NIDA to Advance Its Signaling-Pathway Selective Mu-Opioid Receptor Drug CandidateOpen in a New Window

PHILADELPHIA--(BUSINESS WIRE)--MEBIAS Discovery Receives Grant from NIDA to Advance Its Signaling-Pathway Selective Mu-Opioid Receptor Drug Candidate.

 

Wharton Research Data Services Launches Advanced Research Scholar Program – Offering Onsite Education Program for Global ResearchersOpen in a New Window

PHILADEPHIA--(BUSINESS WIRE)--Wharton Research Data Services Launches Advanced Research Scholar Program – Offering Onsite Education Program for Global Researchers

 

Proxima Clinical Research, Inc. Appoints David T. Novotny as Chief Strategy OfficerOpen in a New Window

HOUSTON--(BUSINESS WIRE)--#CRO--David T. Novotny was recently named Chief Strategy Officer of Proxima Clinical Research, Inc., a leader in clinical trial and strategic services. Mr. Novotny will be a member of the executive management team and drive the strategy of the organization, particularly in the medical device sector. “We are fortunate to have someone of David’s caliber and experience recognize the special things that are happening here and want to be a part of it,” said Kevin Coker, Co-founde

 

TransEnterix Acquires Assets, Intellectual Property and Retains R&D Team from MST Medical Surgery TechnologiesOpen in a New Window

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced that it has acquired substantially all of the assets of MST Medical Surgery Technologies Ltd. (“MST”), an Israel medical technology company, in a cash and stock transaction with a total consideration, further described below. MST is a leader in the field of surgical

 

About BioFlorida

BioFlorida represents nearly 6,000 establishments and research organizations in the biopharmaceutical, medical technology and bioagriculture sectors that collectively employ nearly 83,000 Floridians.

 

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

Email us for a regional Chapter sponsorship.

Connect